ERBB2 and breast carcinoma: Based on the results of the EMILIA clinical trial FDA approved Ado trastuzumab in 2013 for patients with HER2-positive Metastatic breast cancer who received trastuzumab and a taxane separately or in combination previously (Wedam et al. 2020).